Double bull's eye for post-operative intravenous iron in patient blood management: Better outcome and cost-effective

Blood Transfusion

Volumn 12, Issue 1, 2014, Pages 7-9

  Liumbruno, Giancarlo M ^a   Grazzini, Gioia ^a  

^a Fatebenefratelli Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROPLASTY, REPLACEMENT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IRON; MALE; POSTOPERATIVE CARE;

EID: 84894187573     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0227-13     Document Type: Editorial

References (31)

1. Shander A, Knight K, Thurer R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116 (Suppl 7A): 58S-69S.
2. Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 2010; 113: 482-95.
3. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396-407.
4. van Iperen CE, Kraaijenhagen RJ, Biesma DH, et al. Iron metabolism and erythropoiesis after surgery. Br J Surg 1998; 85: 41-5.
5. van Iperen CE, van de Wiel A, Marx JJ. Acute event-related anaemia. Br J Haematol 2001; 115: 739-43.
6. Means RT. Hepcidin and cytokines in anaemia. Hematology 2004; 9: 357-62.
7. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
8. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011; 64: 281-6.
9. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338: 768-72.
10. Auerbach M, Goodnough LT, Shander A. Iron: the new advances in therapy. Best Pract Res Clin Anaesthesiol 2013; 27: 131-40.
11. Means RT Jr. Hepcidin and iron regulation in health and disease. Am J Med Sci 2013; 345: 57-60.
12. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823: 1434-43.
13. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008; 48: 988-1000.
14. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306: 1520-8.
15. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion 2012; 52: 1584-92.
16. Muñoz M, García-Erce JA, Cuenca J, et al; AWGE (Spanish Anaemia Working Group). On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus 2012; 10: 8-22.
17. Cuenca J, García-Erce JA, Martínez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery. Transfusion 2006; 46: 1112-9.
18. Muñoz M, Breymann C, García-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008; 94: 172-83.
19. Krafft A, Breymann C. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 2011; 37: 119-24.
20. Cladellas M, Farré N, Comín-Colet J, et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol 2012; 110: 1021-6.
21. Muñoz M, Gómez-Ramírez S, Cuenca J, et al. Very-shortterm perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion 2013; doi: 10.1111/trf.12195.
22. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2013; doi: 10.1111/trf.12289.
23. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610 .
24. Bailie GR, Hörl WH,Verhoef JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung 2011; 61: 267-75.
25. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health-Syst Pharm 2012; 69: 310-20.
26. Bailie GR, Verhoef JJ. Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population. Clin Adv Hematol Oncol 2012; 10: 101-8.
27. Wong G, Howard K, Hodson E, et al. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrol Dial Transplant 2013; 28: 413-20.
28. Muñoz M, Gómez-Ramírez S, Martín- Montañez E, et al. Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study. Blood Transfus 2014: 12: 40-9.
29. Muñoz M, Ariza D, Campos A, et al. The cost of post-operative shed blood salvage after total knee arthroplasty: an analysis of 1,093 consecutive procedures. Blood Transfus 2013; 11: 260-71.
30. Kaplan RS, Anderson SR. Time-driven activity-based costing. Harv Bus Rev 2004; 82: 131-8.
31. Hofmann A, Ozawa S, Farrugia A, et al. Economic considerations on transfusion medicine and patient blood management. Best Pract Res Clin Anaesthesiol 2013; 27: 59-68.